Comprehensive characterization of responders and non-responders
HLH, TG
In order to investigate the factors that predict patient outcomes in HLH patients treated with dose-escalating ruxolitinib, we analyzed the correlation between response to treatment and common clinical and laboratory features before treatment. We found that most laboratory indicators, including blood cell counts, levels of AST, ALT, T-bil, TG, Fbg, LDH, ferritin, cytokines (IL-2, IL-4, IL-6, IL-10, IFN-5, TNF-α, IL-17A), NK cell activity or genetic defects, did not show any correlation with treatment outcome. In addition, the time from symptom onset to initiation of ruxolitinib treatment and the time to the use of the maximum dose of ruxolitinib were also not related to treatment effectiveness (as shown in Comparison of patients’ characteristics between responders and non-responders before treatment.the valve was expressed as median [range] or mean ± standard deviation.

The only laboratory indicator that showed a statistically significant difference between responders and non-responders to dose-escalating ruxolitinib was the level of sCD25 (p=0.021), as shown in Levels of sCD25 before ruxolitinib between response and non-response to dose-escalating group. *, p<0.05.